GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Liabilities-to-Assets

Outlook Therapeutics (FRA:41O) Liabilities-to-Assets : 3.27 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Outlook Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €177.80 Mil. Outlook Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was €54.31 Mil. Therefore, Outlook Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 3.27.


Outlook Therapeutics Liabilities-to-Assets Historical Data

The historical data trend for Outlook Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Liabilities-to-Assets Chart

Outlook Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.63 0.86 0.80 0.69 1.45

Outlook Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 1.12 1.45 2.12 3.27

Competitive Comparison of Outlook Therapeutics's Liabilities-to-Assets

For the Biotechnology subindustry, Outlook Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outlook Therapeutics's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Liabilities-to-Assets falls into.



Outlook Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Outlook Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Liabilities-to-Assets (A: Sep. 2023 )=Total Liabilities/Total Assets
=43.794/30.266
=1.45

Outlook Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=177.804/54.307
=3.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Outlook Therapeutics  (FRA:41O) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Outlook Therapeutics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Outlook Therapeutics (FRA:41O) Business Description

Traded in Other Exchanges
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics (FRA:41O) Headlines

No Headlines